Cargando…

Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO‐INSIGHTFUL study

BACKGROUND: Poor adherence to topical therapy in psoriasis remains an issue; it is associated with poor clinical outcomes, reduced quality of life and increased costs. Treatment‐related factors leading to poor adherence include lack of efficacy, excessive time applying medication and poor cosmetic c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, C‐H., Papp, K.A., Lophaven, K.W., Skallerup, P., Philipp, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles and Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698702/ https://www.ncbi.nlm.nih.gov/pubmed/28796913 http://dx.doi.org/10.1111/jdv.14515

Ejemplares similares

Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)
por: Narcisi, Alessandra, et al.
Publicado: (2022)

Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest
por: Reich, K., et al.
Publicado: (2015)

Implementation of the PsoWell™ Model for the Management of People with Complex Psoriasis
por: HEWITT, Rachael M., et al.
Publicado: (2021)

Nail psoriasis as a severity indicator: results from the PsoReal study
por: Radtke, Marc A, et al.
Publicado: (2010)

PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis
por: Stein Gold, Linda, et al.
Publicado: (2020)

Spotlight on Topical Long-Term Management of Plaque Psoriasis
por: Carrascosa, Jose Manuel, et al.
Publicado: (2020)

AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis
por: Hercogová, J., et al.
Publicado: (2019)

Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict
por: Iversen, Lars, et al.
Publicado: (2016)

Person-specific outcome measure (PSO) for use in primary and community care
por: Benson, Tim
Publicado: (2021)

Phenotypes of Psoriasis in Patients in Need of Systemic Treatment, and Correlation with Personal Habits, Treatment History and Comorbidities: A Cross-sectional Latent Class Analysis of Data from the Italian PsoReal Registry
por: CAZZANIGA, Simone, et al.
Publicado: (2023)

Low Pneumococcal Vaccination among Patients with Psoriasis in Germany: Results from Vac-Pso
por: Wellmann, Phoebe, et al.
Publicado: (2022)

Phase I randomized study of KHK4083, an anti‐OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis
por: Papp, K.A., et al.
Publicado: (2017)

Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
por: Menter, A., et al.
Publicado: (2016)

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE
por: Papp, K.A., et al.
Publicado: (2015)

A Case of Melanoma in a Patient With Psoriasis Highlighting the Importance of Dermatoscopy and Inflammoscopy
por: Benton, Sarah, et al.
Publicado: (2022)

DICER1 RNase IIIb domain mutations are infrequent in testicular germ cell tumours
por: de Boer, Carmela M, et al.
Publicado: (2012)

Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)
por: Graier, T., et al.
Publicado: (2022)

Psoriasis pathogenesis – Pso p27 constitutes a compact structure forming large aggregates
por: Lysvand, Hilde, et al.
Publicado: (2015)

CoronaBest und PsoBest Bioscience: Neue Ausbaustufen beim Deutschen Psoriasis-Register
por: Gehoff, Mario
Publicado: (2020)

Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire
por: Dauden, Esteban, et al.
Publicado: (2012)

Exploring the Association Between History of Psoriasis (PSO) and Disease Activity in Patients with Psoriatic Arthritis (PsA)
por: Li, Shan-Shan, et al.
Publicado: (2022)

Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate‐to‐severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI‐PSO study
por: Richard, M.‐A., et al.
Publicado: (2020)

AdPSO: Adaptive PSO-Based Task Scheduling Approach for Cloud Computing
por: Nabi, Said, et al.
Publicado: (2022)

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis
por: Blauvelt, A., et al.
Publicado: (2017)

Topical Therapies in Psoriasis
por: Torsekar, R., et al.
Publicado: (2017)

Topical Therapy in Psoriasis
por: Ahmed, SK Shahriar, et al.
Publicado: (2023)

Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Ionic liquids IIIB
por: Rogers, Robin D, et al.
Publicado: (2005)

Particle swarm optimization (PSO)
por: Walker, Brian
Publicado: (2017)

The importance of chemical mechanisms in sonochemical modelling
por: Kalmár, Csanád, et al.
Publicado: (2022)

‘New to me’: changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well(®) patient materials mixed‐methods feasibility study
por: Nelson, P.A., et al.
Publicado: (2017)

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
por: Gooderham, M.J., et al.
Publicado: (2018)

COVID-19 mitigation strategies: A natural experiment highlighting the importance of structure in the prevention and treatment of childhood obesity
por: Brazendale, Keith, et al.
Publicado: (2022)

Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review
por: Papp, Kim A., et al.
Publicado: (2021)

Crystal Structures of the Novel Cytosolic 5′-Nucleotidase IIIB Explain Its Preference for m(7)GMP
por: Monecke, Thomas, et al.
Publicado: (2014)

Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO)
por: Piaserico, Stefano, et al.
Publicado: (2023)

Optical fiber telecommunications IIIB
Publicado: (1997)

Substrate preference of Gen endonucleases highlights the importance of branched structures as DNA damage repair intermediates
por: Bellendir, Stephanie P., et al.
Publicado: (2017)

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study
por: Paul, Carle, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7h8ent1r6e9a42b0tv6ogjphce